In breast cancer patients, RSPO2, RSPO3, and RSPO4 overexpression has been reported, which is associated with hormone receptor‐negative tumor status and for RSPO2 also with reduced patient survival [30, 31]. Here, RSPO3 is linked to breast cancer.